News
IDXG
6.00
NaN%
--
Weekly Report: what happened at IDXG last week (0928-1002)?
Weekly Report · 2d ago
Weekly Report: what happened at IDXG last week (0921-0925)?
Weekly Report · 09/28 10:03
U.S. IPO Weekly Recap: Postponed Deals Put Damper On Fall IPO Market
Seeking Alpha · 09/26 02:40
Weekly Report: what happened at IDXGD last week (0914-0918)?
Weekly Report · 09/21 10:03
Weekly Report: what happened at IDXGD last week (0907-0911)?
Weekly Report · 09/14 10:07
Weekly Report: what happened at IDXGD last week (0831-0904)?
Weekly Report · 09/07 10:02
Weekly Report: what happened at IDXGD last week (0824-0828)?
Weekly Report · 08/31 10:08
Interpace Biosciences announces 1-for-5 reverse split for Nasdaq uplisting
TipRanks · 08/26 20:50
*Interpace Biosciences: Reverse Stk Split Will Become Effective at 12:01 AM ET on Aug 27 >IDXG
Dow Jones · 08/26 20:22
*Interpace Biosciences Announces Reverse Stk Split to Support Proposed Nasdaq Uplisting
Dow Jones · 08/26 20:22
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Barchart · 08/26 15:05
Weekly Report: what happened at IDXG last week (0817-0821)?
Weekly Report · 08/24 10:08
Interpace Diagnostics Shareholders Approve Governance and Equity Plans
TipRanks · 08/21 10:29
Weekly Report: what happened at IDXG last week (0810-0814)?
Weekly Report · 08/17 10:09
Interpace Biosciences GAAP EPS of $0.01, revenue of $9.1M
Seeking Alpha · 08/10 21:02
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Barchart · 08/10 15:35
Weekly Report: what happened at IDXG last week (0803-0807)?
Weekly Report · 08/10 10:05
Weekly Report: what happened at IDXG last week (0727-0731)?
Weekly Report · 08/03 10:05
Weekly Report: what happened at IDXG last week (0720-0724)?
Weekly Report · 07/27 10:08
Weekly Report: what happened at IDXG last week (0713-0717)?
Weekly Report · 07/20 10:05
More
Webull provides a variety of real-time IDXG stock news. You can receive the latest news about Interpace Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About IDXG
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.